FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1713-1720 June 12, 1997 Number 24 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background The risk of malignant myeloid disorders in young children with neurofibromatosis type 1 is 200 to 500 times the normal risk. The gene for neurofibromatosis type 1 (NF1) encodes neurofibromin, a protein that negatively regulates signals transduced by Ras proteins. Genetic and biochemical data support the hypothesis that NF1 functions as a tumor-suppressor gene in immature myeloid cells, but inactivation of both NF1 alleles has not been demonstrated in leukemic cells from patients with neurofibromatosis type 1.

Methods Using an in vitro transcription and translation system, we screened bone marrow samples from 18 children with neurofibromatosis type 1 and myeloid disorders for NF1 mutations that cause a truncated protein. Mutations were confirmed by direct sequencing of genomic DNA from the patients, and from their affected parents, in cases of familial neurofibromatosis type 1.

Results Specimens from 9 of the 18 children contained abnormal peptide fragments, and truncating mutations of the NF1 gene were found in specimens from 8 of these children. The normal NF1 allele was absent in bone marrow samples from five of the eight children. We detected the same mutation in DNA from the affected parent of each child with familial neurofibromatosis type 1.

Conclusions Both alleles of the NF1 gene are inactivated in leukemic cells in some patients with neurofibromatosis type 1. NF1 appears to function as a tumor-suppressor gene in immature myeloid cells.

Source Information

From the Department of Pediatrics, University of California, San Francisco (L.S., B.T., E.C., P.T., K.S.); and Roche Biomedical Laboratories, Research Triangle Park, N.C. (M.C., M.L.).

Address reprint requests to Dr. Shannon at Box 0519, University of California, 513 Parnassus Ave., San Francisco, CA 94143-0519.

Full Text of this Article

This article has been cited by other articles:

• Kehrer-Sawatzki, H, Cooper, D N (2008). Mosaicism in sporadic neurofibromatosis type 1: variations on a theme common to other hereditary cancer syndromes?. J. Med. Genet. 45: 622-631 [Abstract] [Full Text]  
• Balgobind, B. V., Van Vlierberghe, P., van den Ouweland, A. M. W., Beverloo, H. B., Terlouw-Kromosoeto, J. N. R., van Wering, E. R., Reinhardt, D., Horstmann, M., Kaspers, G. J. L., Pieters, R., Zwaan, C. M., Van den Heuvel-Eibrink, M. M., Meijerink, J. P. P. (2008). Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 111: 4322-4328 [Abstract] [Full Text]  
• Flotho, C., Kratz, C. P., Niemeyer, C. M. (2007). How a rare pediatric neoplasia can give important insights into biological concepts: a perspective on juvenile myelomonocytic leukemia. haematol 92: 1441-1446 [Full Text]  
• Matsuda, K., Shimada, A., Yoshida, N., Ogawa, A., Watanabe, A., Yajima, S., Iizuka, S., Koike, K., Yanai, F., Kawasaki, K., Yanagimachi, M., Kikuchi, A., Ohtsuka, Y., Hidaka, E., Yamauchi, K., Tanaka, M., Yanagisawa, R., Nakazawa, Y., Shiohara, M., Manabe, A., Kojima, S., Koike, K. (2007). Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood 109: 5477-5480 [Abstract] [Full Text]  
• Stephens, K., Weaver, M., Leppig, K. A., Maruyama, K., Emanuel, P. D., Le Beau, M. M., Shannon, K. M. (2006). Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood 108: 1684-1689 [Abstract] [Full Text]  
• Schubbert, S., Lieuw, K., Rowe, S. L., Lee, C. M., Li, X., Loh, M. L., Clapp, D. W., Shannon, K. M. (2005). Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106: 311-317 [Abstract] [Full Text]  
• Chan, R. J., Leedy, M. B., Munugalavadla, V., Voorhorst, C. S., Li, Y., Yu, M., Kapur, R. (2005). Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 105: 3737-3742 [Abstract] [Full Text]  
• Look, A. T. (2005). Molecular Pathogenesis of MDS. ASH Education Book 2005: 156-160 [Abstract] [Full Text]  
• Le, D. T., Kong, N., Zhu, Y., Lauchle, J. O., Aiyigari, A., Braun, B. S., Wang, E., Kogan, S. C., Le Beau, M. M., Parada, L., Shannon, K. M. (2004). Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 103: 4243-4250 [Abstract] [Full Text]  
• Hiatt, K., Ingram, D. A., Huddleston, H., Spandau, D. F., Kapur, R., Clapp, D. W. (2004). Loss of the Nf1 Tumor Suppressor Gene Decreases Fas Antigen Expression in Myeloid Cells. Am. J. Pathol. 164: 1471-1479 [Abstract] [Full Text]  
• Loh, M. L., Vattikuti, S., Schubbert, S., Reynolds, M. G., Carlson, E., Lieuw, K. H., Cheng, J. W., Lee, C. M., Stokoe, D., Bonifas, J. M., Curtiss, N. P., Gotlib, J., Meshinchi, S., Le Beau, M. M., Emanuel, P. D., Shannon, K. M. (2004). Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103: 2325-2331 [Abstract] [Full Text]  
• Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., Shannon, K. M. (2004). Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl. Acad. Sci. USA 101: 597-602 [Abstract] [Full Text]  
• Hirai, H. (2003). Molecular Mechanisms of Myelodysplastic Syndrome. Jpn J Clin Oncol 33: 153-160 [Abstract] [Full Text]  
• Ingram, D. A., Wenning, M. J., Shannon, K., Clapp, D. W. (2003). Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. Blood 101: 1984-1986 [Abstract] [Full Text]  
• Ingram, D. A., Zhang, L., McCarthy, J., Wenning, M. J., Fisher, L., Yang, F.-C., Clapp, D. W., Kapur, R. (2002). Lymphoproliferative defects in mice lacking the expression of neurofibromin: functional and biochemical consequences of Nf1 deficiency in T-cell development and function. Blood 100: 3656-3662 [Abstract] [Full Text]  
• Iversen, P. O., Emanuel, P. D., Sioud, M. (2002). Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood 99: 4147-4153 [Abstract] [Full Text]  
• Arceci, R. J., Longley, B. J., Emanuel, P. D. (2002). Atypical Cellular Disorders. ASH Education Book 2002: 297-314 [Abstract] [Full Text]  
• Kratz, C. P., Emerling, B. M., Bonifas, J., Wang, W., Green, E. D., Beau, M. M. L., Shannon, K. M. (2002). Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. Blood 99: 372-374 [Abstract] [Full Text]  
• Zhu, Y., Romero, M. I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E. J., Marth, J. D., Parada, L. F. (2001). Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 15: 859-876 [Abstract] [Full Text]  
• Reuter, C. W. M., Morgan, M. A., Bergmann, L. (2000). Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood 96: 1655-1669 [Abstract] [Full Text]  
• Emanuel, P. D., Snyder, R. C., Wiley, T., Gopurala, B., Castleberry, R. P. (2000). Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 95: 639-645 [Abstract] [Full Text]  
• Ingram, D. A., Yang, F.-C., Travers, J. B., Wenning, M. J., Hiatt, K., New, S., Hood, A., Shannon, K., Williams, D. A., Clapp, D. W. (2000). Genetic and Biochemical Evidence that Haploinsufficiency of the Nf1 Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates In Vivo. JEM 191: 181-188 [Abstract] [Full Text]  
• Dorschner, M. O., Sybert, V. P., Weaver, M., Pletcher, B. A., Stephens, K. (2000). NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet 9: 35-46 [Abstract] [Full Text]  
• Gutmann, D. H. (1999). Learning Disabilities in Neurofibromatosis 1: Sizing Up the Brain. Arch Neurol 56: 1322-1323 [Full Text]  
• Mahgoub, N., Taylor, B. R., Gratiot, M., Kohl, N. E., Gibbs, J. B., Jacks, T., Shannon, K. M. (1999). In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor on Nf1-Deficient Hematopoietic Cells. Blood 94: 2469-2476 [Abstract] [Full Text]  
• Mahgoub, N., Taylor, B. R., Beau, M. M. L., Gratiot, M., Carlson, K. M., Atwater, S. K., Jacks, T., Shannon, K. M. (1999). Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. Blood 93: 3617-3623 [Abstract] [Full Text]  
• Luna-Fineman, S., Shannon, K. M., Atwater, S. K., Davis, J., Masterson, M., Ortega, J., Sanders, J., Steinherz, P., Weinberg, V., Lange, B. J. (1999). Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients. Blood 93: 459-466 [Abstract] [Full Text]  
• Wang, Q., Lasset, C., Desseigne, F., Frappaz, D., Bergeron, C., Navarro, C., Ruano, E., Puisieux, A. (1999). Neurofibromatosis and Early Onset of Cancers in hMLH1-deficient children. Cancer Res. 59: 294-297 [Abstract] [Full Text]  
• Iversen, P. O., Sioud, M. (1998). Modulation of Granulocyte-Macrophage Colony-Stimulating Factor Gene Expression by a Tumor Necrosis Factor alpha Specific Ribozyme in Juvenile Myelomonocytic Leukemic Cells. Blood 92: 4263-4268 [Abstract] [Full Text]  
• Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N.-K. V., Lovett, B. D., Nowell, P. C., Blair, I. A., Rebbeck, T. R. (1998). Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA 95: 13176-13181 [Abstract] [Full Text]  
• Side, L. E., Emanuel, P. D., Taylor, B., Franklin, J., Thompson, P., Castleberry, R. P., Shannon, K. M. (1998). Mutations of the NF1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis, Type 1 . Blood 92: 267-272 [Abstract] [Full Text]  
• Zhang, Y.-Y., Vik, T. A., Ryder, J. W., Srour, E. F., Jacks, T., Shannon, K., Wade Clapp, D. (1998). Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines. JEM 187: 1893-1902 [Abstract] [Full Text]  
• Lakkis, M., Epstein, J. (1998). Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125: 4359-4367 [Abstract]  
• Sherman, L. S., Atit, R., Rosenbaum, T., Cox, A. D., Ratner, N. (2000). Single Cell Ras-GTP Analysis Reveals Altered Ras Activity in a Subpopulation of Neurofibroma Schwann Cells but Not Fibroblasts. J. Biol. Chem. 275: 30740-30745 [Abstract] [Full Text]  
• Hiatt, K. K., Ingram, D. A., Zhang, Y., Bollag, G., Clapp, D. W. (2001). Neurofibromin GTPase-activating Protein-related Domains Restore Normal Growth in Nf1-/- Cells. J. Biol. Chem. 276: 7240-7245 [Abstract] [Full Text]